Navigation Links
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Date:10/26/2008

- Ninety-six week ARTEMIS data presented at ICAAC -

BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (<50 copies/mL) at week 96, compared with 71 percent of patients taking lopinavir/ritonavir 800 mg/200 mg once daily (or 400 mg/100 mg twice daily), each with a fixed dose of emtricitabine and tenofovir disoproxil fumarate.

Results from the study, known as ARTEMIS, were presented today at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. ARTEMIS is a 192-week study comparing the efficacy and safety of the protease inhibitors (PIs) PREZISTA/r and lopinavir/r in treatment-naive adults with HIV (those who have never taken HIV medication before). PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

At 48 weeks, the primary objective of ARTEMIS was reached when PREZISTA/r was demonstrated to be non-inferior to lopinavir/r for virologic response (confirmed HIV RNA < 50 copies/mL). The difference between the treatment arms was not significant at week 48. The pre-planned safety and efficacy analysis at 96 weeks was a secondary endpoint. At 96 weeks, the study showed PREZISTA/r was non-inferior to lopinavir/r for virologic response. The estimated difference in virologic response between the treatment groups was eight percent and was statistically significant (95 percent confidence interval 1.8; 14.7). The 96-week results from ARTEMIS will be submitted to the FDA.

"This study offers the healthcare provider community long-term efficacy and safety data for PREZISTA in treatment-naive adult patients," said Tony Mills, M.D., ART
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Following US and European approvals of Elekta,s ... Drug Administration (CFDA) has cleared the radiation therapy system ... According to the International Agency for Research on Cancer, ... every year in China 1 ... liver and esophageal cancers 2 . Versa HD is ...
(Date:9/29/2014)... Research and Markets has announced the ... and Forecasts, 2012-2018" report to their offering. ... billion by 2016. The North American segment accounts for nearly ... Europe claims approximately 30% (2018). Asia-Pacific ... of 11.4% driving a market value of US$728 million by ...
(Date:9/29/2014)... 29, 2014  On Oct. 2, some 24,000 Lilly ... company,s seventh Global Day of Service. Building on Lilly,s ... together in a single, coordinated effort to improve the ... "I,m so proud of this tradition, and of ... to strengthening the communities around the world where we ...
Breaking Medicine Technology:Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 2Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 4Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 5Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 2Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 3
... affiliated medical groups -- Sharp Rees-Stealy and Sharp Community ... possible designation for quality care given by the California ... 2011 Standards of Excellence program. CAPG is one of ... groups. "We are grateful to be recognized ...
... Calif., Sept. 20, 2011 CMC Biologics and ... companies have entered into a long-term commercial supply ... intravenous recombinant factor IX (rFIX) product, for the ... hemophilia B. Under the terms of the agreement, ...
Cached Medicine Technology:Sharp HealthCare Medical Groups Recognized for "Elite" Care 2Sharp HealthCare Medical Groups Recognized for "Elite" Care 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:9/30/2014)... AutoTex PINK proudly offers pink ... in support of breast cancer awareness and research in ... non-profits to “go pink” -- supporting walks, runs and ... a woman-owned company that is among the nation’s leading ... partnering with their customers to raise breast cancer awareness ...
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon be ... effort, however most are out of mind in 30. Why? , ... of "spend more time with children", try something easy to do ... a reminder, daily life gets in the way and efforts to ... Goals out of sight equals goals out of mind. , ...
(Date:9/30/2014)... Miraca Life Sciences (MLS), the nation’s largest ... at the annual meeting of the American College of ... Scientific Meeting and Postgraduate Course in Philadelphia, Pa., on ... Life Sciences will be at booth 711 to share ... The research posters for ACG provide a wide range ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take place ... at the Youth Town campus (3641 Youth Town Road ... festival, which will offer music, food and games. Admission ... show, arts and crafts fair, music, championship barbeque competition, ... McQueen and Mater from the hit Disney movie “Cars” ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2
... with advanced prostate cancer suggest they can be good ... study found a 20-year survival rate for 80 percent ... beyond the prostate, known as cT3 prostate cancer, and ... prostate gland. Previously, patients found to have cT3 prostate ...
... using cells from the interior of the nose could help ... treatable stages, according to a study conducted by researchers ... ATS 2011 International Conference. "Our data suggests that evaluating ... surface of the nose may serve as a non-invasive approach ...
... As Americans head toward attics, roofs and yards to freshen ... cleaning can lead to a spring visit to the hospital. ... on a stepladder, and more than 41,000 suffered injuries while ... Product Safety Commission. In addition, over 127,000 were injured while ...
... databases in 2010, researchers looked at the distribution ... health departments or national organizations (such as The ... Association/American Stroke Association). They found that 24 percent ... Notably, in the eight states that have ...
... --,Caring for a loved one who is ill is always ... dementia may face an increased risk for cognitive problem or ... the May issue of the Journal of the American ... their own mental health and ability to care for their ...
... , FRIDAY, May 13 (HealthDay News) -- Chest compressions ... of chest injury, according to new research. The ... Journal of Manipulative and Physiological Therapeutics , measured and ... extremely rigorous and found all to be well under the ...
Cached Medicine News:Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Spring Cleaning Lands Many Americans in Hot Water 2Health News:Older Caregivers at Greater Risk for Cognitive Decline 2Health News:Chiropractic Spinal Manipulation Won't Cause Chest Injuries, Study Contends 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: